

To: [REDACTED] 5.1.2e [REDACTED] @ftcon.co.uk' [REDACTED] 5.1.2e [REDACTED] @ftcon.co.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @imperial.ac.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @soton.ac.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @wales.nhs.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @rivm.nl]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @hscni.net]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @nhs.net]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @nhslothian.scot.nhs.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @nhslothian.scot.nhs.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @warwick.ac.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @rug.nl]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @rug.nl]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @UHBristol.nhs.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @dhsc.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @dhsc.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @gov.scot]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @gov.scot]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @gov.wales]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @gov.wales]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @health-ni.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @mhra.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]; [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] @phe.gov.uk]

From: 5.1.2e (Respiratory Medicine)
Sent: Mon 3/29/2021 8:12:25 AM
Subject: RE: OFFICIAL SENSITIVE - Letter from MHRA and JCVI statement on Phase 2
Received: Mon 3/29/2021 8:12:37 AM

Dear All,

Before everyone spends a lot of effort offering suggestions regarding the paragraph on safety and MHRA, please can I confirm that refinement of the wording in that paragraph can only be done once we know what MHRA are putting in their Statement. (MHRA were still at work last night.)

We all want transparency and sufficient information given to the public for informed decision making. This is also MHRA's responsibility and I am sure they will fulfil this. There are intense comms efforts supporting MHRA.

I believe PHE are developing patient information and a GB paragraph regarding thrombosis + thrombocytopenia, also awaiting harmonisation with MHRA. Dear Mary, please can you confirm/update?

If there are any show-stoppers in the rest of the JCVI statement, please raise these. We are seeking to have the JCVI Statement 'ready-to-do' aside from the safety/MHRA paragraph.

Many thanks

5.1.2e

五

You can also move points off the grid by dragging them.

B. L. S. G. Iyer

5-102

5.1.2e

dubbel

5.1.2e

dubbel

5.1.2e

5.1.2e

3 - 3

dubbel